Apersys AG
PrivateLast Round
Series A
Dec 9, 2024
Total Funding Raised
$12.78M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Apersys AG is a medical technology company that develops and manufactures a novel long-term normothermic organ perfusion system designed to preserve and assess livers outside the human body.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology
Business Model
B2B
Customer Profile
Hardware Sales, Hardware + Subscription, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Apersys AG Comparables
Compare Apersys AG with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Terumo Corporation | 79% | |
| Getinge AB | 78% | |
| Xvivo Perfusion | 76% | |
Apersys AG Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Dec 9, 2024 | ||||
| Seed | Oct 25, 2024 |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 10, 2026
Open roles increased to 5, 3.6x the trailing average.
- Aug 3, 2026
Open roles increased to 3, 3x the trailing average.
Apersys AG Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Apersys AG's valuation, stock price, and market status.